Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases.
Mohamed Mokhtar M MostafaKhadijah S AlghamdiNesreen S AhmedDina Abed BakhotmahTamer S SalehPublished in: Journal of enzyme inhibition and medicinal chemistry (2021)
A new set of 4,6,7,8-tetrahydroquinolin-5(1H)-ones were designed as cytotoxic agents against breast cancer cell line (MCF-7) and synthesised under ultrasonic irradiation using chitosan decorated copper nanoparticles (CS/CuNPs) catalyst. The new compounds 4b, 4j, 4k, and 4e exhibited the most potent cytotoxic activity of IC50 values (0.002 - 0.004 µM) comparing to Staurosporine of IC50; 0.005 μM. The latter derivatives exhibited a promising safety profile against the normal human WI38 cells of IC50 range 0.0149 - 0.048 µM. Furthermore, the most promising cytotoxic compounds 4b, 4j were evaluated as multi-targeting agents against the RTK protein kinases; EGFR, HER-2, PDGFR-β, and VEGFR-2. Compound 4j showed promising inhibitory activity against HER-2 and PDGFR-β of IC50 values 0.17 × 10-3, 0.07 × 10-3 µM in comparison with the reference drug sorafenib of IC50; 0.28 × 10-3, 0.13 × 10-3 µM, respectively. In addition, 4j induced apoptotic effect and cell cycle arrest at G2/M phase preventing the mitotic cycle in MCF-7 cells.
Keyphrases
- cell cycle arrest
- cell death
- pi k akt
- induced apoptosis
- breast cancer cells
- endothelial cells
- small cell lung cancer
- signaling pathway
- drug delivery
- cancer therapy
- emergency department
- cell proliferation
- oxidative stress
- epidermal growth factor receptor
- drug induced
- endoplasmic reticulum stress
- anti inflammatory
- high glucose
- ionic liquid
- reduced graphene oxide
- diabetic rats
- room temperature
- amino acid
- adverse drug
- carbon dioxide
- clinical evaluation
- breast cancer risk
- childhood cancer